

Regional Drugs Testing Laboratory

Directorate General of Health Services, Guwahati (India) - 781022 Fax: 0361-2338555/2330555 Phone No.0361 2338555

Email:rdtlguwahati@cdsco.nic.in

FORM 13 (See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER SECTION 25(1) OF THE DRUGS AND COSMETICS ACT. 1940

Name of Inspector from whom received

: Mrs. C. Ramdinmawii, Assistant Director (F and D)

C.M.O. Office,

Champhai-796321 Mizoram

Serial No. and date of Inspector's memorandum

: 020/IPA-CPI/24, 16-DEC-2024

3. Number of Sample

: NIL

4. Date of receipt

: 31-DEC-2024

Names of drugs purporting to be contained in the sample: Ferrous Sulphate and Folic Acid Tablets I.P.

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
LSD/GUW/2024- 25/1856	GUW/LS/2024- 25/1876	CFR-W27	Mar-2024	Feb-2026	Cyano Pharma (P) Ltd., 115- C, Industrial Estate, Pologround, Indore-452 015

6. Condition of seals on

[the packet or on portion of sample or container]

Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing: From 05-Feb-2025 To 13-Mar-2025

COMPOSITION

Each sugar coated tablet contains: Dried Ferrous Sulphate IP 200 mg.

(Eq. to Ferrous Elemental Iron 60 mg.) Folic Acid I.P. 0.5 mg.

Protocol Applied: I.P. 2022

Sr No.	Test Name	Result	Limits	
1	Description	Red colored, round, bi-convex, coated tablets, in blister pack.	NA	
2	Identification	Gives positive test for Dried Ferrous Sulphate & Folic Acid.	NA	
3	Average weight	0.3612 g	NA	
4	Disintegration	Complies. (Time taken for disintegration 38 minutes and 19 seconds)	NMT 60 minutes	
5	Uniformity of content	Complies for Folic Acid.	NA	

<u>Assay</u>

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Folic acid	1.0007 mg/Tablet	0.5 mg/Tablet	200.14	NLT 90 %	I.P. 2022

2	Dried Ferrous Sulphate equivalent to Elemental Iron	59.7 mg/Tablet	60 mg/Tablet	99.5	90 % to 110 %	I.P. 2022
---	---	----------------	-----------------	------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 18-MAR-2025

GOVERNMENT ANALYST

----- END OF REPORT -----

